NCT02175433 is a Phase 1 clinical trial of AGS67E in Relapsed Lymphoid Malignancy, sponsored by Astellas Pharma Global Development, Inc..

Who is sponsoring NCT02175433?

NCT02175433 is sponsored by Astellas Pharma Global Development, Inc..

What drugs are being tested in NCT02175433?

Interventions in NCT02175433: AGS67E.

What condition does NCT02175433 study?

NCT02175433 studies Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy.

Is NCT02175433 still recruiting?

NCT02175433 is currently completed. Last updated 1 November 2024.

Last reviewed 2024-11-01 · How we verify

NCT02175433

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Completed Phase 1 Last updated 1 November 2024

What this trial tests

Phase 1 trial testing AGS67E in Relapsed Lymphoid Malignancy in 71 participants. Completed in 29 October 2019.

Timeline

14 October 2014

Primary endpoint
29 October 2019

29 October 2019

Quick facts

Lead sponsor	Astellas Pharma Global Development, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	71
Start date	14 October 2014
Primary completion	29 October 2019
Estimated completion	29 October 2019
Sites	5 locations across Canada, United States

Drugs / interventions tested

AGS67E — full drug profile →

Conditions studied

Relapsed Lymphoid Malignancy — all drugs for Relapsed Lymphoid Malignancy →
Refractory Lymphoid Malignancy — all drugs for Refractory Lymphoid Malignancy →

Sponsor

Astellas Pharma Global Development, Inc. — full company profile →

Who can join

18 and older, any sex, with Relapsed Lymphoid Malignancy or Refractory Lymphoid Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AGS67E both without and with myeloid growth factor (GF) in subjects with refractory or relapsed lymphoid malignancies. Immunogenicity and anticancer activity of AGS67E will also be assessed.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Exploration of the antibody-drug conjugate clinical landscape.
Maecker H, Jonnalagadda V, Bhakta S, Jammalamadaka V, et al · · 2023 · cited 90× · PMID 37639687 · DOI 10.1080/19420862.2023.2229101
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
Yu B, Liu D. · · 2019 · cited 70× · PMID 31500657 · DOI 10.1186/s13045-019-0786-6
Biomaterials from the sea: Future building blocks for biomedical applications.
Wan MC, Qin W, Lei C, Li QH, et al · · 2021 · cited 69× · PMID 33997505 · DOI 10.1016/j.bioactmat.2021.04.028
CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. · · 2021 · cited 56× · PMID 34620233 · DOI 10.1186/s13287-021-02595-0
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
Chu Y, Zhou X, Wang X. · · 2021 · cited 48× · PMID 34090506 · DOI 10.1186/s13045-021-01097-z
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.
Newman DJ, Cragg GM. · · 2017 · cited 43× · PMID 28353637 · DOI 10.3390/md15040099
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, Muñoz-Calleja C. · · 2017 · cited 39× · PMID 29387053 · DOI 10.3389/fimmu.2017.01936

Verify or expand the search:

Other trials of AGS67E

Trials testing the same drug.

NCT02610062 — A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Sub · Phase 1 · terminated

Other Astellas Pharma Global Development, Inc. trials

Trials by the same sponsor.

NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07475806 — A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep · Phase 2 · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07287995 — A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02175433 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Global Development, Inc.
Last refreshed: 1 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02175433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing